|
|
Article: Alkermes Starts Phase III Of Inhaled Insulin Product.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
After the January approval of the first inhaled insulin product in the U.S., Alkermes Inc. and others have forged ahead with their own programs in hopes of gaining a share of a multi-billion-dollar diabetes market.
Now Cambridge, Mass.-based Alkermes appears to be positioned to bring to market the second inhaled insulin product, its AIR Inhaled Insulin System (AIR system). It has started an additional Phase III registrational study in Type II diabetes patients that will compare A1C - an average measure of glucose over a three-month period - between the AIR system and injectable pre-meal insulin.
Alkermes began its Phase III ...